Nykode Therapeutics ASA Dividend Analysis
NYKD.XOSL
This company does not have a meaningful dividend profile under this framework.
Based on TTM and annual data · Not a buy/sell signal
Score Breakdown
Safety
40% of composite
Growth
35% of composite
Income
25% of composite
Composite = Safety (0) × 0.40 + Growth (0) × 0.35 + Income (0) × 0.25 = 0
Dividend Safety
Earnings Payout
Not reported
FCF Payout
–
FCF Coverage
–
Dividend Growth
Per Share (TTM)
$0.00
Growth Streak
–
CAGR
–
Dividend history
| Fiscal year | Per share | Change |
|---|---|---|
| 2024 | $0.10 |
Each payment counts toward the fiscal year it is paid for, so a final dividend paid in spring belongs to the year before. Figures are adjusted for stock splits, so a fall is a cut.
Computed from company filings. Ex-dividend and payment dates are not part of those filings, so they are not shown here. This is analysis, not investment advice.
Yield History
Does Nykode Therapeutics ASA (NYKD.XOSL) pay a dividend?
Frequently asked
Does Nykode Therapeutics ASA (NYKD.XOSL) pay a dividend?+
No. Nykode Therapeutics ASA (NYKD.XOSL) does not currently pay a dividend. The last payment in our data was in 2024, and nothing has been paid since.
How does Nykode Therapeutics ASA return cash to shareholders?+
It largely does not. Nykode Therapeutics ASA pays no dividend and we do not see a meaningful reduction in share count over the last twelve months, so cash is being retained in the business or spent on growth rather than returned. That is common for companies reinvesting heavily, and it means your return depends entirely on the share price.
Could Nykode Therapeutics ASA afford to pay a dividend?+
Not currently. Nykode Therapeutics ASA's free cash flow is negative at -$27 million, meaning the business consumed cash over the period rather than generating it. A company funding a dividend from cash it is not producing would be paying shareholders out of its balance sheet or borrowings, which is not sustainable.
Which healthcare companies do pay dividends?+
Our Healthcare sector page ranks the companies we cover by dividend score, which combines payout safety, free cash flow coverage and growth record. If income is what you are after, start there rather than with Nykode Therapeutics ASA.
Peers
Biotechnology · Pick stocks to compare with NYKD.XOSL
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing NYKD.XOSL
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.